EPS: As of FY2025 Q2, the actual value is USD -0.15.

EBIT: As of FY2025 Q2, the actual value is USD -4.974 M.

Segment Revenue

• The company operates as one segment and does not provide specific segmented revenue data.

Operational Metrics

• Net Loss: The net loss for the three months ended June 30, 2025, was $4,974,000, compared to $4,956,000 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $10,458,000, compared to $9,562,000 in 2024.
• Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $5,037,000, a slight decrease from $5,090,000 in 2024. For the six months ended June 30, 2025, operating expenses were $10,538,000, up from $9,874,000 in 2024.
• General and Administrative Expenses: Decreased by 24% to $1,711,000 for the three months ended June 30, 2025, compared to $2,246,000 in 2024. For the six months ended June 30, 2025, these expenses decreased by 19% to $3,720,000 from $4,602,000 in 2024.
• Research and Development Expenses: Increased by 17% to $3,326,000 for the three months ended June 30, 2025, compared to $2,844,000 in 2024. For the six months ended June 30, 2025, these expenses increased by 29% to $6,818,000 from $5,272,000 in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used was $7,922,000, compared to $7,013,000 in 2024.
• Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used was $1,899,000, compared to $98,000 in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided was $10,700,000, compared to $84,000 in 2024.

Future Outlook and Strategy

• Core Business Focus: The company is focused on commercializing its HeartBeam System, which has received FDA clearance. The company plans to launch the product once it receives FDA clearance for its 12L synthesis software.
• Non-Core Business: The company has initiated an Early Access Program to gather feedback on its HeartBeam System and has announced a strategic collaboration with AccurKardia to enhance its product offering.
• Priority: The company is prioritizing the development and commercialization of its HeartBeam System and expects no material commercial revenue in 2025.